The yearly MetaSystems Distributor Meeting (DM), brought into life in 2002 as a platform to gather all international partners of MetaSystems and other members of the global MetaSystems family, just ended last week. The DM is being organized in turns by MetaSystems Headquarters, MetaSystems USA (MGI), and MetaSystems Asia. Since MGI is celebrating its 25th anniversary in 2018 they decided to choose a special location: Nassau, The Bahamas!
XL t(6;14) CCND3/IGH DF
Translocation/Dual Fusion Probe
- Order Number
- Package Size
- 100 µl
The most frequent primary abnormalities in multiple myeloma (MM) are trisomies of odd-numbered chromosomes or translocations involving the immunglobulin heavy chain (IgH) gene locus. The most common MM-associated IGH translocations are t(11;14), t(4;14), t(6;14), t(14;16) and t(14;20) in the order of their occurrence. The consequence of these rearrangements is the dysregulation of genes juxtaposed to transcriptional enhancers in the IGH locus. Prognosis and risk stratification strongly depends on the detection and interpretation of cytogenetic primary abnormalities. t(14;16) and t(14;20) are considered as high risk, t(4;14) as intermediate risk and t(6;14) and t(11;14) as standard risk cytogenetic aberrations in patients with MM based on FISH testing. Secondary aberrations are also influencing the outcome.
Cyclins of the D-family are essential for the transition of the G1 to the S-Phase during the cell cycle. t(6;14)(p21;q32) moves the cyclin D3 gene in proximity to 3´ IGH enhancer sequences and is associated with cyclin D3 overexpression. The chromosomal translocation has been reported as a rare and recurrent event not only in myeloma but also in other B-cell malignancies as diffuse large B-cell lymphoma.
- Multiple Myeloma and Plasma Cell Neoplasms (MM)
Two green (2G) and two orange (2O) signals.
Aberrant Cell (typical results):
One green (1G), one orange (1O), and two green-orange colocalization/fusion signals (2GO) resulting from a reciprocal translocation between the relevant loci.
- Shaughnessy et al (2001) Blood 98:217-223
- Sonoki et al (2001) Blood 98:2837-2844
- Rajan and Rajkumar (2015) Blood Cancer J. 5:e365